MedPath

Circadian Intervention to Improve Cardiometabolic Health

Not Applicable
Recruiting
Conditions
Sleep
Time Restricted Feeding
Lifestyle Factors
Eating Habit
Sleep Hygiene
Insulin Sensitivity
Cardiometabolic Syndrome
Type 2 Diabetes
Overweight and Obesity
Interventions
Behavioral: Circadian Intervention
Registration Number
NCT05943626
Lead Sponsor
University of Utah
Brief Summary

The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a randomized controlled trial, with circadian intervention and control (healthy lifestyle) groups. The circadian intervention is designed to reduce nighttime light exposure and after-dinner snack food intake. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).

Detailed Description

The study is a randomized controlled trial with control and circadian intervention groups. Group allocation will be blinded to research staff and participants until the conclusion of the baseline segment. The circadian intervention group will receive counseling and instruction to reduce evening and nighttime light exposure, increase morning room light and sunlight exposure, and complete all food consumption at least 4 hours before bedtime. Participants randomized to control will maintain their habitual food intake and sleep habits in their home environment for \~8 weeks. Both groups will have equal contact time with the study team.

Prior to enrollment participants will complete an clinical overnight sleep disorders screening. Baseline consists of an \~1-week ambulatory real-world monitoring segment. Following baseline participants will be randomized to the control or intervention groups for the 8 week experimental segment. Throughout the study sleep duration will be monitored using an actiwatch wrist-device and a daily electronic sleep log. At the end of the baseline and experimental segments participants will complete overnight laboratory visits to assess insulin sensitivity and circadian timing by oral glucose tolerance test and dim light melatonin onset, respectively.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  1. Age: 18-45 years old; equal numbers of men and women
  2. Body mass index (BMI): 25.0-34.9 kg/m2,
  3. Sleep Habits: habitual self-reported average total sleep time (TST) <6.5 hours per night for prior 6 months
Exclusion Criteria
  1. Clinically diagnosed sleep disorder or major psychiatric illness
  2. Evidence of significant organ dysfunction or disease (e.g., diagnosed diabetes, cardiovascular disease, or kidney disease)
  3. Use of prescription drugs or substances known to influence sleep or glucose metabolism
  4. Shift-work: current or history of within last year
  5. Weight change: >10% of body weight over prior six months
  6. Experiencing menopause or post-menopausal
  7. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program
  8. Currently pregnant or planning to become pregnant, or currently lactating.
  9. Currently smoking
  10. Alcohol intake >3 drinks per day or >14 drinks per week

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention GroupCircadian InterventionCircadian-based intervention focused on timing of light exposure and food intake.
Primary Outcome Measures
NameTimeMethod
Insulin sensitivity change from baselineChange from baseline to end of the ~8 week experimental segment

Oral Glucose Tolerance Test (OGTT), Matsuda Index

Secondary Outcome Measures
NameTimeMethod
Timing of central circadian clock change from baselineChange from baseline to end of the ~8 week experimental segment

Quantified as dim-light melatonin onset from salivary melatonin samples

Plasma ceramides change from baselineChange from baseline to end of the ~8 week experimental segment

Fasting plasma samples will be analyzed for plasma ceramides using targeted metabolomics

Average (per week) self-reported sleep duration change from baselineAnalyzed as change from baseline for each week of the ~8 week experimental segment

Daily electronic sleep logs will be used to track sleep and waketimes during the ambulatory monitoring phases of the study

Average (per week) sleep satisfaction change from baselineAnalyzed as change from baseline for each week of the ~8 week experimental segment

5 point likert scale on daily sleep log (1 = very good; 5 = very poor)

Average (per week) nightly total sleep time change from baselineAnalyzed as change from baseline for each week of the ~8 week experimental segment

Analyzed by wrist-actigraphy

Average (per week) timing of food intake change from baselineChange from baseline to week 8 of the ~8 week experimental segment

Time of day 50% of calories are consumed collected by picture based food diaries. Average per week will consist of 2 weekdays and 1 weekend day for baseline and final week of intervention

Average (per week) daytime alertness change from baselineAnalyzed as change from baseline for each week of the ~8 week experimental segment

5 point likert scale on daily sleep log (1= most alert; 5 = not alert at all)

Trial Locations

Locations (1)

College of Health Research Complex--University of Utah

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath